Trial Profile

Phase I, first-in-human Proof-of-Concept, randomized, double-blind study of VK0214 in X-Linked Adrenoleukodystrophy (X-ALD)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VK 0214 (Primary)
Indications Adrenoleucodystrophy
Focus Adverse reactions; First in man; Proof of concept
Sponsors Viking Therapeutics

Most Recent Events

28 Jul 2021 According to a Viking Therapeutics media release, the study achieved both primary and secondary objectives.
28 Jul 2021 Status changed from recruiting to completed, according to a Viking Therapeutics media release.
17 Jun 2021 Results published in the Viking Therapeutics Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com